American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 533.e1-533.e8, November 2008

Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary

  • Elin Ødegaard, MD

      Affiliations

    • Department of Obstetrics and Gynaecology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Ben Davidson, MD, PhD

      Affiliations

    • Faculty of Medicine, University of Oslo, Oslo, Norway
    • Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
    • ,
  • Vibeke Engh, MD

      Affiliations

    • Department of Pathology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Mathias Onsrud, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynaecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway
    • ,
  • Anne Cathrine Staff, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynaecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway

Received 18 October 2007; received in revised form 12 December 2007; accepted 2 April 2008. published online 05 June 2008.

Objective

The objective of the study was to analyze circulating endoglin concentration in ovarian carcinoma and evaluate a prognostic role for calprotectin and endoglin in effusions in advanced-stage disease.

Study Design

Preoperative plasma concentration of endoglin from women with benign ovarian tumors (n = 71), borderline ovarian tumors (BOT, n = 39), and ovarian carcinomas (n = 89) was analyzed with an enzyme-linked immunosorbent assay, as were endoglin and calprotectin concentrations in effusions from 164 women with advanced-stage ovarian carcinoma.

Results

Median endoglin plasma concentration was higher in the BOT group as compared with both control and invasive carcinoma groups (4.9 vs 4.5 and 4.3 ng/mL, P = .04 and P = .02), whereas the difference between the control and invasive group was not statistically significant (4.5 vs 4.3 ng/mL, P = .08). Endoglin and calprotectin effusion concentrations did not correlate with survival.

Conclusion

Circulating endoglin is not elevated in advanced ovarian carcinoma. This is in contrast to the situation in breast and gastric cancer.

Key words: biomarker, borderline tumors of the ovary, calprotectin, endoglin, ovarian carcinoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Cite this article as: Ødegaard E, Davidson B, Engh V, et al. Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol 2008;199:533.e1-533.e8.

 This study was supported by a research grant from the Regional Health Authority, Eastern Norway (to E.Ø.).

 Reprints not available from the authors.

PII: S0002-9378(08)00395-5

doi:10.1016/j.ajog.2008.04.004

American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 533.e1-533.e8, November 2008

Article Tools

* Image Usage & Resolution